Clinical Trial Update: A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluating the safety and preliminary efficacy of vaccinations with allogeneic dendritic cells fused with autologous tumor-derived cells in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Allogeneic dendritic cell vaccine (electrofused with autologous tumor-derived cells) (dendritic cell vaccine)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED